ClinicalTrials.gg
RecruitingNCT05868616NIME-CRTUpdated Oct 15, 2026

Non-Invasive Method for Evaluation of Cardiac Resynchronization Therapy

An observational study in Heart Failure, Pacemaker DDD and Cardiomyopathies, sponsored by Oslo University Hospital. Recruiting at 1 site in Norway. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-10-15.

Sponsored by Oslo University Hospital · Observational

How we know

From the registry’s dates

  • Started Mar 2023; still recruiting 3 years 8 months later.
Updated Oct 15, 2026Primary completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
80
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 11 studies in Heart Failure by Oslo University Hospital — 4 open to participants now, 4 under way, none of them phase 3. Heart Failure · Oslo University Hospital.

Started
2023
the only one that year
Observational
4 of 11
3 open now
Registered
9th of 11
by date

Among the 11 studies in Heart Failure by Oslo University Hospital, this one is the only one that started in 2023, is one of 4 observational ones, and was the 9th registered.

Heart Failure

6,340 studies on the registry are indexed under Heart Failure; 1,397 are open to participants now.

Browse Heart Failure studies →

Open to participants now

4 of the 11 studies in Heart Failure by Oslo University Hospital are open now, in 10 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Who these studies take

Of the 968 Heart Failure studies recruiting now, 691 (71%) set no upper age limit and 90 (9%) stop at 75 or younger; 64 take children under 18; 97 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies in Heart Failure by Oslo University Hospital, or all of them as a file.
02

Study summary

Left bundle branch block (LBBB) exists in about 25% of patients with congestive heart failure and is associated with worsened prognosis. Cardiac resynchronization therapy (CRT) has been one of the most important advancements in the past two decades for patients with LBBB heart failure. However, 30-40% of patients receiving a CRT do not benefit from it. In this study, the investigators will test a noninvasive device to evaluate acute effect of CRT during implantation and at follow-up CRT controls. In addition, echocardiography will be performed during CRT turned ON and OFF to visualize the changes in intraventricular flow and functional parameters of the heart.

03

Conditions studied

  • Heart Failure
  • Pacemaker DDD
  • Cardiomyopathies
  • Heart Diseases
  • Cardiovascular Diseases
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Patients referred for CRT implantation according to European Society of Cardiology (ESC) guidelines (2021) or postoperative control at Oslo University Hospital.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients referred for CRT implantation or postoperative control at Oslo University Hospital based on the European Society of Cardiology (ESC) guidelines (2021), and criteria below:

    1. Sinus rhythm.
    2. class II / III heart failure on diagnosis and on optimal medical therapy.
    3. Left bundle branch block.
    4. QRS duration ≥ 130 ms.
    5. ≤ 40%.
    6. Patients must have echocardiography examination before implantation
    7. obtained from the patient.

Exclusion criteria

Exclusion Criteria:

  1. Age \< 18 years and > 80 years;
  2. Ongoing atrial fibrillation;
  3. Complete atrioventricular block
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
80 participants (estimated)
Patient registry
No
Biospecimen retention
Samples with dna

Groups and cohorts

  • Group 1 - Implantation

    Patients admitted for CRT implantation according to current ESC/AHA guidelines

    Device: Cardiac Resynchronization Therapy (CRT)

  • Group 2 - 6 months control

    Patients admitted for 6 months routine checkups of their CRT devices

    Device: Cardiac Resynchronization Therapy (CRT)

Interventions

  • DeviceCardiac Resynchronization Therapy (CRT)

    Cardiac resynchronization therapy (CRT) is a modality of cardiac pacing used in patients with left ventricular (LV) systolic dysfunction and dyssynchronous ventricular activation that provides simultaneous or nearly simultaneous electrical activation of the LV and right ventricle (RV) via stimulation of the LV and RV (biventricular pacing) or LV alone.

06

What researchers measure

Primary outcomes

  1. Reverse remodelling at 6 months follow-up

    Measured by left ventricular end-systolic volume reduction of at least 15% assessed by echocardiography

    Time frame: 6 months

Secondary outcomes

  1. Hospitalization

    * all cause hospitalization * heart failure hospitalization defined by symptom, signs and biochemistry (NT-proBNP)

    Time frame: 2 years

  2. Mortality

    * all cause death * sudden cardiac death * cardiovascular death * transplantation

    Time frame: 2 years

  3. New York Heart Association (NYHA) Functional Classification

    The New York Heart Association (NYHA) functional classification provides a simple way of classifying the extent of heart failure. It places patients in one of four categories based on how much they are limited during physical activity; the limitations/symptoms are in regard to normal breathing and varying degrees in shortness of breath and/or angina.

    Time frame: 2 years

  4. Minnesota Living with Heart Failure Questionnaire

    Minnesota living with heart failure questionnaire is a validated patient-oriented measure of the adverse effects of heart failure on a patient's life.

    Time frame: 2 years

  5. Packer clinical composite score

    The Packer clinical composite score classifies each patient into 1 of 3 categories (improved, worsened, unchanged), and is determined using clinical outcomes (hospitalizations, death, heart transplant), heart failure status, and patient symptoms (defined by a higher New York Heart Association (NYHA) functional classification and quality of life measured using the Minnesota Living With Heart Failure Questionnaire). Each endpoint will be assessed at 6, 12, 18, and 24 months.

    Time frame: 2 years

  6. 6 minute walk test

    The 6 minute walk test is a sub-maximal exercise test used to assess aerobic capacity and endurance. The distance covered over a time of 6 minutes is used as the outcome by which to compare changes in performance capacity. The test will be performed in group 1 before implantation and at 6 months control to evaluate response to intervention.

    Time frame: 6 months

07

Study locations

1 of 1 sites recruiting
08

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Undecided

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2023 (actual). Primary completion is estimated for Mar 2028, 60 months after the start.

Of 799 non-industry observational studies under Heart Failure, half reached primary completion within 45 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 100. This study's planned 60 months is above that.

Counting every sponsor, half of 982 studies reached it within 41 months; a quarter within 23 and three quarters within 89.

Primary completion moved once since we started tracking on Sep 25, 2026: Mar 2027 → Mar 2028, on Oct 15, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Apr 26, 2023
First posted
May 22, 2023
StartActual
Mar 21, 2023
Primary completionEst.
Mar 2028was Mar 2027
CompletionEst.
Mar 2031
Last update
Oct 15, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Mar 2027→Mar 2028
Oct 15, 2026
Show all 1 update
  1. Oct 15, 2026
    Primary completion Mar 2027→Mar 2028
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05868616
Collaborators
South-Eastern Norway Regional Health Authority, Norwegian Health Association
Responsible party
Espen Remme (Dr.ing, Oslo University Hospital) — Principal investigator
First posted
May 22, 2023
Start date
Mar 21, 2023
Primary completion
Mar 2028 (estimated)
Completion
Mar 2031 (estimated)
Last update
Oct 15, 2026

Study contacts

Espen W. Remme, Dr.ing
Contact
espen.remme@medisin.uio.no
004723071413
Marit Witsø, MD
Contact
mhwitso@medisin.uio.no
004723071402
Espen W. Remme, Dr.ing
study director · Oslo University Hospital
Marit Witso, MD
principal investigator · Oslo University Hospital
Hongxing Luo, MD, PhD
principal investigator · Oslo University Hospital

Oversight

FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion